share_log

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

Benzinga ·  Jun 28 01:28

B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment